Retinoic acid [302-79-4]

Referência HY-14649-100mg

Tamanho : 100mg

Marca : MedChemExpress

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Description

Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.

IC50 & Target[2][5]

PPARβ/δ

17 nM (Kd)

PPARα

103 nM (Kd)

PPARγ

178 nM (Kd)

Human Endogenous Metabolite

 

PPARα

14 nM (IC50)

PPARγ

14 nM (IC50)

RARβ

14 nM (IC50)

CRABP-II

 

Cellular Effect
Cell Line Type Value Description References
3LLD122 IC50
33 μM
Compound: ATRA
Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%
Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%
[PMID: 10956204]
BE(2)-C IC50
6.7 μM
Compound: ATRA
Antiproliferative activity against human BE2C cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay
Antiproliferative activity against human BE2C cells assessed as reduction in cell growth incubated for 96 hrs by MTT assay
[PMID: 38432288]
COLO 205 IC50
37 μM
Compound: ATRA
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
[PMID: 20405849]
COS-7 EC50
0.2 nM
Compound: ATRA
Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
Activity at human RARgamma ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
[PMID: 19058965]
COS-7 EC50
0.6 nM
Compound: ATRA
Transactivation of GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
Transactivation of GAL4-fused mouse RARgamma-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
[PMID: 30792038]
COS-7 EC50
1.2 nM
Compound: ATRA
Transactivation of GAL4-fused mouse RARalpha-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
Transactivation of GAL4-fused mouse RARalpha-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
[PMID: 30792038]
COS-7 EC50
1.2 nM
Compound: ATRA
Transactivation of GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
Transactivation of GAL4-fused mouse RARbeta-LBD expressed in COS-7 cells after 24 hrs by bright-Glo reagent based assay
[PMID: 30792038]
COS-7 EC50
12 nM
Compound: ATRA
Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
Activity at human RARbeta ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
[PMID: 19058965]
COS-7 EC50
17 nM
Compound: ATRA
Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
Activity at human RARalpha ligand binding domain expressed in COS7 cells co-transfected with Gal4-DBD assessed as transcriptional activation after 16 hrs by Gal4 response element-driven luciferase reporter gene assay
[PMID: 19058965]
CV-1 EC50
>2000 nM
Compound: (all-E)-RA
Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha
Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha
[PMID: 9572893]
CV-1 EC50
>2 μM
Compound: (all-E)-RA
Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha
Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha
[PMID: 9572893]
CV-1 EC50
0.7 nM
Compound: RA
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay
10.1016/0960-894X(95)00588-K
CV-1 EC50
0.7 nM
Compound: Retinoic acid
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma
[PMID: 7490725]
CV-1 EC50
1 nM
Compound: RA
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay
10.1016/0960-894X(95)00588-K
CV-1 EC50
1 nM
Compound: Retinoic acid
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta
[PMID: 7490725]
CV-1 EC50
10 nM
Compound: ATRA
Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells
[PMID: 8308867]
CV-1 EC50
1015 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha
Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha
[PMID: 12482435]
CV-1 EC50
105 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta
[PMID: 8709094]
CV-1 EC50
1084 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha
Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha
[PMID: 8709094]
CV-1 EC50
1100 nM
Compound: RA
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay
10.1016/0960-894X(95)00588-K
CV-1 EC50
1100 nM
Compound: ATRA
Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells
[PMID: 8308867]
CV-1 EC50
1211 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta
Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta
[PMID: 12482435]
CV-1 EC50
1225 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma
Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma
[PMID: 8709094]
CV-1 EC50
1394 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta
Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta
[PMID: 8709094]
CV-1 EC50
1400 nM
Compound: RA
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay
10.1016/0960-894X(95)00588-K
CV-1 EC50
1400 nM
Compound: ATRA
Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells
[PMID: 8308867]
CV-1 EC50
19 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma
Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma
[PMID: 12482435]
CV-1 EC50
2 nM
Compound: (all-E)-RA
Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR beta
Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR beta
[PMID: 9572893]
CV-1 EC50
20 nM
Compound: RA
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma
[PMID: 8978832]
CV-1 EC50
22 nM
Compound: (all-E)-RA
Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR alpha
Transcriptional activation in CV-1 cells expressing retinoid A receptor RAR alpha
[PMID: 9572893]
CV-1 EC50
33 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma
[PMID: 8709094]
CV-1 EC50
350 nM
Compound: ATRA
Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells
[PMID: 8308867]
CV-1 EC50
436 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha
Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha
[PMID: 12482435]
CV-1 EC50
459 nM
Compound: RA
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha
[PMID: 8978832]
CV-1 EC50
563 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha
[PMID: 8709094]
CV-1 EC50
6 nM
Compound: (all-E)-RA
Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma
Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma
[PMID: 9572893]
CV-1 EC50
7 nM
Compound: RA
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay
10.1016/0960-894X(95)00588-K
CV-1 EC50
7 nM
Compound: Retinoic acid
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha
[PMID: 7490725]
CV-1 EC50
78 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta
Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta
[PMID: 12482435]
CV-1 EC50
80 nM
Compound: ATRA
Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells
[PMID: 8308867]
CV-1 EC50
87 nM
Compound: RA
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta
Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta
[PMID: 8978832]
CV-1 EC50
900 nM
Compound: RA
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay
Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay
10.1016/0960-894X(95)00588-K
CV-1 EC50
900 nM
Compound: ATRA
Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells
Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells
[PMID: 8308867]
CV-1 EC50
961 nM
Compound: ATRA
Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma
Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma
[PMID: 12482435]
CWR22R GI50
25.11 μM
Compound: 1, ATRA
Growth inhibition of human CWR22Rv1 cells by MTT assay
Growth inhibition of human CWR22Rv1 cells by MTT assay
[PMID: 25634130]
DU-145 GI50
11.64 μM
Compound: ATRA, Tretinoin
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human DU145 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 25701251]
F9 ED50
1.0 x 10-10M
Compound: 1a
Ability to induce differentiation of mouse F9 embryonal carcinoma cells.
Ability to induce differentiation of mouse F9 embryonal carcinoma cells.
[PMID: 2836589]
F9 ED50
0.1 nM
Compound: 1
Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay
Ability to displace 3 uM retinoid and [3H]all-trans-retinoic acid in F9 embryonal carcinoma cells using F9 Plasminogen Activator releasing assay
[PMID: 2738885]
F9 ED50
1.5 nM
Compound: 1
Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay
Ability to displace [3H]all-trans-retinoic acid from F9 embryonal carcinoma cells, was assessed in a F9 laminin release assay
[PMID: 2738885]
F9 IC50
0.1 nM
Compound: 7, trans- RA
Induction of terminal differentiation in mouse F9 cells assessed by measuring secreted plasminogen activator activity after 3 days
Induction of terminal differentiation in mouse F9 cells assessed by measuring secreted plasminogen activator activity after 3 days
[PMID: 17489579]
Fibroblast IC50
10 μM
Compound: retinoic acid
Inhibition of UVB irradiation-induced MMP1 production in human dermal fibroblasts after 48 hrs
Inhibition of UVB irradiation-induced MMP1 production in human dermal fibroblasts after 48 hrs
[PMID: 18029185]
HEK-293T IC50
28.7 μM
Compound: Retinoic acid
Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
[PMID: 23122865]
HEK-293T IC50
301.3 μM
Compound: Retinoic acid
Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis
[PMID: 23122865]
HL-60 CC50
23 nM
Compound: ATRA; RA
Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue staining based assay
Antiproliferative activity against human HL-60 cells assessed as cell growth inhibition measured after 72 hrs by trypan blue staining based assay
[PMID: 33895500]
HL-60 EC50
5 nM
Compound: RA
Transglutaminase activity in HL-60 cdm-1 cells
Transglutaminase activity in HL-60 cdm-1 cells
[PMID: 7636843]
HL-60 EC50
5 nM
Compound: RA
Induction of transglutaminase (TGase) activity in HL-60 cells
Induction of transglutaminase (TGase) activity in HL-60 cells
[PMID: 8784454]
HL-60 ED50
1.25 μM
Compound: ATRA
In vitro for the differentiation induction activity determined in the human myeloid leukemic cell line HL-60
In vitro for the differentiation induction activity determined in the human myeloid leukemic cell line HL-60
[PMID: 10956204]
HL-60 ED50
120 nM
Compound: (all-E)-RA
Induction of HL-60 cells differentiation over 4 days
Induction of HL-60 cells differentiation over 4 days
[PMID: 9572893]
HL-60 ED50
2.4 nM
Compound: RA
Differentiation inducing activity towards human promyelocytic leukemia cell line HL-60 assayed by nitroblue tetrazolium reduction
Differentiation inducing activity towards human promyelocytic leukemia cell line HL-60 assayed by nitroblue tetrazolium reduction
[PMID: 2704028]
HL-60 ED50
2.4 nM
Compound: retinoic acid
The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes was determined by nitro blue tetrazolium (NBT) reduction assay
The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes was determined by nitro blue tetrazolium (NBT) reduction assay
[PMID: 8182710]
HL-60 ED50
2.4 x 10-9M
Compound: 1
Concentration required for 50% inhibition of differentiation-inducing activity against human promyelocytic leukemia cell line HL-60
Concentration required for 50% inhibition of differentiation-inducing activity against human promyelocytic leukemia cell line HL-60
[PMID: 1738149]
HL-60 ED50
2.4 x 10-9M
Compound: 1 (Retinoic acid)
Ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes.
Ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes.
[PMID: 2329565]
HL-60 ED50
2.4 x 10-9M
Compound: RA
Differentiation inducing activity towards human promyelocytic leukemia cell line HL-60 assayed by nitroblue tetrazolium reduction
Differentiation inducing activity towards human promyelocytic leukemia cell line HL-60 assayed by nitroblue tetrazolium reduction
[PMID: 2704028]
HL-60 ED50
2.4 x 10-9M
Compound: Retinoic acid
Effective concentration required for induction of differentiation of HL-60 cells into mature granulocytes.
Effective concentration required for induction of differentiation of HL-60 cells into mature granulocytes.
[PMID: 15261256]
HL-60 ED50
2.4 x 10-9M
Compound: Retinoic acid
The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte
The ability to induce differentiation of human promyelocytic leukemia HL-60 cell line to mature granulocyte
[PMID: 2709376]
HL-60 ED50
2.4 x 10-9M
Compound: retinoic acid
Compound was tested for differentiation-inducing activity against human promyelocytic leukemia cell line HL-60
Compound was tested for differentiation-inducing activity against human promyelocytic leukemia cell line HL-60
[PMID: 2795600]
HL-60 ED50
2.4 x 10-9M
Compound: retinoic acid
The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes was determined by nitro blue tetrazolium (NBT) reduction assay
The ability to induce differentiation of human promyelocytic leukemia cell line HL-60 to mature granulocytes was determined by nitro blue tetrazolium (NBT) reduction assay
[PMID: 8182710]
HL-60 ED50
50 nM
Compound: 1
Compound was evaluated for the retinoid-induced differentiation of the human myeloid leukemia cell line HL-60 using trans-retinoic acid as the standard.
Compound was evaluated for the retinoid-induced differentiation of the human myeloid leukemia cell line HL-60 using trans-retinoic acid as the standard.
[PMID: 1992144]
HL-60 IC50
11 μM
Compound: ATRA
In vitro cytotoxicity against HL60 cells.
In vitro cytotoxicity against HL60 cells.
[PMID: 11128648]
HL-60 IC50
11 μM
Compound: ATRA(all-trans-retinoic acid)
Cytostatic activity against HL-60 cells
Cytostatic activity against HL-60 cells
[PMID: 10585206]
HL-60 IC50
18 μM
Compound: ATRA
In vitro inhibition of HL60 cell proliferation
In vitro inhibition of HL60 cell proliferation
[PMID: 11428925]
HT-29 CC50
4.3 μM
Compound: ATRA; RA
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay
[PMID: 33895500]
HT-29 IC50
4.3 μM
Compound: ATRA
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
[PMID: 20405849]
LNCaP GI50
10.33 μM
Compound: ATRA, Tretinoin
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human LNCAP cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 25701251]
LNCaP GI50
47.86 μM
Compound: 1, ATRA
Growth inhibition of human LNCAP cells by MTT assay
Growth inhibition of human LNCAP cells by MTT assay
[PMID: 25634130]
LNCaP IC50
10 μM
Compound: 1
Growth inhibition of human LNCaP cells after 6 days by MTT assay
Growth inhibition of human LNCaP cells after 6 days by MTT assay
[PMID: 15615521]
LNCaP IC50
5 × 10-7M
Compound: ATRA
Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay
Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay
[PMID: 19375825]
LNCaP IC50
5 x 10-1μM
Compound: ATRA
Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay
Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay
[PMID: 19375825]
LNCaP IC50
5 x 10-7M
Compound: ATRA
Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay
Antiproliferative activity against human LNCAP cells after 48 hrs by MTT assay
[PMID: 19375825]
MCF7 CC50
20 nM
Compound: ATRA; RA
Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by cell counting assay
Antiproliferative activity in human MCF7 cells assessed as cell growth inhibition measured after 72 hrs by cell counting assay
[PMID: 33895500]
MCF7 GI50
12.39 μM
Compound: ATRA, Tretinoin
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 25701251]
MCF7 IC50
0.58 μM
Compound: 1
Growth inhibition of human MCF7 cells after 6 days by MTT assay
Growth inhibition of human MCF7 cells after 6 days by MTT assay
[PMID: 15615521]
MCF7 IC50
584.5 nM
Compound: 1
Antiproliferative effect against human MCF7 cells
Antiproliferative effect against human MCF7 cells
[PMID: 15615521]
MCF7 IC50
6.14 μM
Compound: atRA
Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs
[PMID: 33139111]
MDA-MB-231 GI50
10.85 μM
Compound: ATRA
Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay
Growth inhibition of human MDA-MB-231 cells after 5 days by MTT assay
[PMID: 18543902]
MDA-MB-231 GI50
14.12 μM
Compound: 1, ATRA
Growth inhibition of human MDA-MB-231 cells by MTT assay
Growth inhibition of human MDA-MB-231 cells by MTT assay
[PMID: 25634130]
MDA-MB-231 IC50
16 μM
Compound: atRA
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
[PMID: 33139111]
MDA-MB-453 GI50
9.51 μM
Compound: ATRA, Tretinoin
Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-453 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 25701251]
MDA-MB-468 GI50
14.12 μM
Compound: 1, ATRA
Growth inhibition of human MDA-MB-468 cells by MTT assay
Growth inhibition of human MDA-MB-468 cells by MTT assay
[PMID: 25634130]
ME-180 CC50
80 nM
Compound: ATRA; RA
Antiproliferative activity against human ME-180 cells assessed as inhibition of cell growth
Antiproliferative activity against human ME-180 cells assessed as inhibition of cell growth
[PMID: 33895500]
MIA PaCa-2 IC50
9.5 μM
Compound: ATRA
Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50%
Concentration required to inhibit the colony formation of pancreatic human (PACA) cell lines by 50%
[PMID: 10956204]
MOLM-13 CC50
1.24 μM
Compound: ATRA; RA
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth measured after 96 hrs by WST-8 assay
Antiproliferative activity against human MOLM-13 cells assessed as inhibition of cell growth measured after 96 hrs by WST-8 assay
[PMID: 33895500]
NB-4 CC50
1.5 μM
Compound: ATRA; RA
Antiproliferative activity against human NB-4 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
Antiproliferative activity against human NB-4 cells assessed as inhibition of cell growth measured after 96 hrs by MTT assay
[PMID: 33895500]
NB-4 ED50
610 nM
Compound: (all-E)-RA
Induction of NB4 cell differentiation
Induction of NB4 cell differentiation
[PMID: 9572893]
Panel leukemia (Carcinoma cell lines) ED50
2.4 x 10-9M
Compound: Retinoic acid
Effective dose for differentiation -inducing activity against human promyelocytic leukemia cells
Effective dose for differentiation -inducing activity against human promyelocytic leukemia cells
[PMID: 3184125]
PC-3 CC50
12.7 μM
Compound: ATRA; RA
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth measured after 24 hrs by MTT assay
[PMID: 33895500]
PC-3 GI50
12.64 μM
Compound: ATRA, Tretinoin
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 25701251]
PC-3 GI50
36.3 μM
Compound: 1, ATRA
Growth inhibition of human PC3 cells by MTT assay
Growth inhibition of human PC3 cells by MTT assay
[PMID: 25634130]
PC-3 GI50
7.6 μM
Compound: ATRA
Growth inhibition of human PC3 cells after 5 days by MTT assay
Growth inhibition of human PC3 cells after 5 days by MTT assay
[PMID: 18543902]
PC-3 IC50
2 μM
Compound: 1
Growth inhibition of human PC3 cells after 6 days by MTT assay
Growth inhibition of human PC3 cells after 6 days by MTT assay
[PMID: 15615521]
Raji IC50
15.4 nM
Compound: retinoic acid
Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs
Inhibition of TPA-induced Epstein-Barr virus early antigen activation in Raji cells after 48 hrs
[PMID: 17503850]
Raji IC50
482 molar ratio
Compound: retinoic acid
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells
[PMID: 16441065]
SK-BR-3 GI50
22.9 μM
Compound: 1, ATRA
Growth inhibition of human SKBR3 cells by MTT assay
Growth inhibition of human SKBR3 cells by MTT assay
[PMID: 25634130]
SK-BR-3 IC50
1.7 nM
Compound: ATRA (Retinoic acid)
Inhibition of ER-negative human breast cancer cell SK-BR-3 proliferation
Inhibition of ER-negative human breast cancer cell SK-BR-3 proliferation
[PMID: 12372520]
T47D GI50
0.82 μM
Compound: ATRA, Tretinoin
Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human T47D cells assessed as reduction in cell viability after 48 hrs by MTT assay
[PMID: 25701251]
T47D IC50
0.006 μM
Compound: 1
Growth inhibition of human T47D cells after 6 days by MTT assay
Growth inhibition of human T47D cells after 6 days by MTT assay
[PMID: 15615521]
T47D IC50
200 nM
Compound: ATRA (Retinoic acid)
Inhibition of ER positive human breast cancer cell T-47D proliferation
Inhibition of ER positive human breast cancer cell T-47D proliferation
[PMID: 12372520]
In Vitro

Retinoic acid (All-trans-retinoic acid, ATRA) is a highly potent derivative of vitamin A that is required for virtually all essential physiological processes and functions because of its involvement in transcriptional regulation of over 530 different genes. Retinoic acid exerts its actions by serving as an activating ligand of nuclear retinoic acid receptors (RARα-γ), which form heterodimers with retinoid X receptors (RXRα-γ)[1].
Retinoic acid (RA) bound to PPARα and PPARγ with a low affinity demonstrated by Kd values of 100-200 nM. In contrast, Retinoic acid associates with PPARβ/δ with a Kd of 17 nM, revealing both high affinity and isotype selectivity[2].
Undifferentiated P19 cells express the Retinoic acid (RA) receptors RARα, RARβ, RARγ, and PPARβ/δ, as well as the Retinoic acid -binding proteins CRABP-II and FABP5. Induction of differentiation by treatment of cells with Retinoic acid results in transient up-regulation of CRABP-II and down-regulation of FABP5 that are observed at the level of both the respective proteins and mRNAs. Following the initial decrease, the level of both FABP5 protein and mRNA increases to attain a 2-2.5-fold higher level in mature neurons as compared with undifferentiated P19 cells. Induction of differentiation does not markedly affect the levels of either RARα or PPARβ/δ. The level of RARγ mRNA decreases by about 5-fold by day 4 and remained low in mature neurons[3].
Retinoic acid (RA) is a morphogen derived from retinol (vitamin A) that plays important roles in cell growth, differentiation, and organogenesis. The Retinoic acid interacts with retinoic acid receptor (RAR) and retinoic acid X receptor (RXR) which then regulate the target gene expression[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvant et solubilité
In Vitro: 

DMSO : 50 mg/mL (166.42 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.3285 mL 16.6423 mL 33.2845 mL
5 mM 0.6657 mL 3.3285 mL 6.6569 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Calculateur de molarité

  • Calculateur de dilution

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Pureté et documentation
Références

Você também pode estar interessado nos seguintes produtos:



Referência
Descrição
Cond.
Price Bef. VAT